Literature DB >> 9349397

Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels.

E Delpón1, C Valenzuela, P Gay, L Franqueza, D J Snyders, J Tamargo.   

Abstract

OBJECTIVE: The aim of this study was to analyze the effects of loratadine on a human cardiac K+ channel (hKv1.5) cloned from human ventricle and stably expressed in a mouse cell line.
METHODS: Currents were studied using the whole-cell configuration of the patch-clamp technique in Ltk- cells transfected with the gene encoding hKv1.5 channels.
RESULTS: Loratadine inhibited in a concentration-dependent manner the hKv1.5 current, the apparent affinity being 1.2 +/- 0.2 microM. The blockade increased steeply between -30 and 0 mV which corresponded with the voltage range for channel opening, thus suggesting that the drug binds preferentially to the open state of the channel. The apparent association and dissociation rate constants were (3.6 +/- 0.5) x 10(6).M-1.s-1 and 3.7 +/- 1.6.s-1, respectively. Loratadine, 1 microM, increased the time constant of deactivation of tail currents elicited on return to -40 mV after 500 ms depolarizing pulses to +60 mV from 36.2 +/- 3.4 to 64.9 +/- 3.6 ms (n = 6, P < 0.01), thus inducing a 'crossover' phenomenon. Application of trains of pulses at 1 Hz lead to a progressive increase in the blockade reaching a final value of 48.6 +/- 4.3%. Recovery from loratadine-induced block at -80 mV exhibited a time constant of 743.0 +/- 78.0 ms. Finally, the results of a mathematical stimulation of the effects of loratadine, based on an open-channel block model, reproduced fairly well the main effects of the drug.
CONCLUSIONS: The present results demonstrated that loratadine blocked hKv1.5 channels in a concentration-, voltage-, time- and use-dependent manner but only at concentrations much higher than therapeutic plasma levels in man.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349397     DOI: 10.1016/s0008-6363(97)00121-1

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  22 in total

1.  Cardiotoxicity of second-generation antihistamines.

Authors:  D J Roberts
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

4.  Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.

Authors:  Hye Sook Ahn; Sung Eun Kim; Hyun-Jong Jang; Myung-Jun Kim; Duck-Joo Rhie; Shin-Hee Yoon; Yang-Hyeok Jo; Myung-Suk Kim; Ki-Wug Sung; Seong Yun Kim; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-21       Impact factor: 3.000

5.  Effects of propafenone on K currents in human atrial myocytes.

Authors:  A Seki; N Hagiwara; H Kasanuki
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Modeling the effect of Kv1.5 block on the canine action potential.

Authors:  Joachim Almquist; Mikael Wallman; Ingemar Jacobson; Mats Jirstrand
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

7.  Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner.

Authors:  Yun Ju Chae; Dae Hun Kim; Hong Joon Lee; Ki-Wug Sung; Oh-Joo Kwon; Sang June Hahn
Journal:  Pflugers Arch       Date:  2014-09-18       Impact factor: 3.657

8.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.

Authors:  F J de Abajo; L A Rodríguez
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

9.  Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release.

Authors:  Mazen El-Hammadi; Nisrine Awad
Journal:  AAPS PharmSciTech       Date:  2011-11-19       Impact factor: 3.246

10.  Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Pflugers Arch       Date:  2010-08-24       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.